FAP inhibitor (Boehringer-Ingelheim/Capital Medical Univ/Harvard Medical School)

N/A

Report date: 2025/01/26 18:04:55
NME

Base Information

Drug NameFAP inhibitor (Boehringer-Ingelheim/Capital Medical Univ/Harvard Medical School)
Drug Alias Namefibroblast activation protein inhibitor (Boehringer-Ingelheim/Capital Medical Univ/Harvard Medical School)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast activation protein alpha inhibitors
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsLiver Cirrhosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesCapital Medical UniversityHarvard Medical SchoolBoehringer Ingelheim International Gmbh
Inactive CompaniesN/A
Active IndicationsLiver Cirrhosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A